Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC34A2 | O95436 | 1/20 | 0.47 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
| ▸ | MAP3K7 | O43318 | 2/20 | 0.43 |
| ▸ | IRAK1 | P51617 | 2/20 | 0.43 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.43 |
| ▸ | GLS | O94925 | 1/20 | 0.42 |
| ▸ | BRAF | P15056 | 5/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.40 |
| ▸ | RAF1 | P04049 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL46746 | 0.94 | SLC34A2 (0.47) | SLC34A2CHRM3MAP3K7IRAK1IRAK4 | |
| SCHEMBL19596297 | 0.94 | SLC34A2 (0.50) | SLC34A2CHRM3MAP3K7IRAK1IRAK4 | |
| SCHEMBL15432581 | 0.93 | SLC34A2 (0.46) | SLC34A2CHRM3MAP3K7IRAK1IRAK4 | |
| SCHEMBL15420846 | 0.92 | SLC34A2 (0.48) | SLC34A2CHRM3MAP3K7IRAK1IRAK4 | |
| SCHEMBL46985 | 0.92 | SLC34A2 (0.48) | SLC34A2CHRM3MAP3K7IRAK1IRAK4 | |
| SCHEMBL44766 | 0.91 | SLC34A2 (0.46) | SLC34A2CHRM3MAP3K7IRAK1IRAK4 | |
| SCHEMBL46748 | 0.89 | CHRM3 (0.58) | SLC34A2CHRM3MAP3K7IRAK1IRAK4 | |
| SCHEMBL46725 | 0.89 | CHRM3 (0.56) | SLC34A2CHRM3MAP3K7IRAK1IRAK4 | |
| SCHEMBL5998433 | 0.88 | SLC34A2 (0.47) | SLC34A2CHRM3MAP3K7IRAK1IRAK4 | |
| SCHEMBL46663 | 0.88 | MAP3K7 (0.47) | SLC34A2CHRM3MAP3K7IRAK1IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2590656-B1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX INC (US) | 2017-11-15 | — | — | EP | disclosed |
| US-20170037010-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. | 2017-02-09 | — | — | US | disclosed |
| EP-2591354-B1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX INC (US) | 2016-09-07 | — | — | EP | disclosed |
| US-9301951-B2 | Compounds and methods for inhibiting phosphate transport | ARDELYX, INC. (US) | 2016-04-05 | — | — | US | disclosed |
| US-20150164876-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. | 2015-06-18 | — | — | US | disclosed |
| US-8916569-B2 | Compounds and methods for inhibiting phosphate transport | ARDELYX, INC. (US) | 2014-12-23 | — | — | US | disclosed |
| US-20140023611-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. | 2014-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150164876-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | SLC34A2, SLC34A1, SLC10A2 | SLC34A2 1/4885CHRM3 3213/4885MAP3K7 3883/4885 |
| US-20170037010-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | SLC34A2, SLC34A1, SLC10A2 | SLC34A2 1/4885CHRM3 3213/4885MAP3K7 3883/4885 |
| US-20140023611-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | SLC10A2, SLC34A2, SLC34A3 | SLC34A2 2/4885CHRM3 3775/4885MAP3K7 3833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.